Is Tafasitamab included in medical insurance?

Tafasitamab (Tafasitamab) is a cancer drug that is used first in combination with another drug called lenalidomide and then alone to treat adults with diffuse large B-cell lymphoma (DLBCL) whose cancer has come back or has stopped responding to other treatments and who are unable to undergo an autologous stem cell transplant (a transplant in which stem cells are harvested from the patient's own body). Diffuse large B-cell lymphoma is rare, and tafracetamab is designated an "orphan drug" (a drug used for rare diseases).

Tafasitamab contains active substancestafasitamab is a monoclonal antibody, a protein designed to recognize and attach to specific structures in certain cells of the body. Tafaracetamab, in particular, is designed to attach to CD19, a protein found on the surface of cancer cells. When attached to CD19, the drug is expected to stimulate the immune system (the body's natural defense system) to attack and kill cancer cells, thereby slowing the progression of the disease. Tafaracetam may cause serious side effects, including infusion-related reactions, bone marrow suppression, infection, and harm to the unborn baby.

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.